Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 10/20 | 0.51 |
| ▸ | AR | P10275 | 5/20 | 0.48 |
| ▸ | PGR | P06401 | 2/20 | 0.48 |
| ▸ | HTR1A | P08908 | 7/20 | 0.47 |
| ▸ | HTR2B | P41595 | 7/20 | 0.47 |
| ▸ | HTR5A | P47898 | 6/20 | 0.47 |
| ▸ | HTR2C | P28335 | 5/20 | 0.47 |
| ▸ | HTR1D | P28221 | 5/20 | 0.47 |
| ▸ | HTR1B | P28222 | 5/20 | 0.47 |
| ▸ | HTR2A | P28223 | 5/20 | 0.47 |
| ▸ | HTR6 | P50406 | 5/20 | 0.47 |
| ▸ | HTR1E | P28566 | 3/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | HTR3A | P46098 | 1/20 | 0.44 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.43 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.43 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7576242 | 0.81 | AR (0.44) | AR | |
| SCHEMBL29805087 | 0.80 | AR (0.58) | ARPGRMAOAMAOBIMPDH2 | |
| SCHEMBL2786569 | 0.80 | AR (0.58) | ARPGRIMPDH2IMPDH1 | |
| SCHEMBL4504936 | 0.80 | AR (0.58) | ARPGRMAOAMAOBIMPDH2 | |
| SCHEMBL7570638 | 0.79 | CYP19A1 (0.49) | ARMAOAMAOB | |
| SCHEMBL7569269 | 0.78 | CSNK2A2 (0.41) | AR | |
| SCHEMBL1133173 | 0.78 | KCNN4 (0.54) | HTR7ARPGRMAOAMAOB | |
| SCHEMBL7569928 | 0.77 | GABRA1 (0.38) | AR | |
| SCHEMBL7572092 | 0.77 | CYP19A1 (0.56) | MAOAMAOB | |
| SCHEMBL7569476 | 0.75 | MCL1 (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020019527-A1 | Substituted phenyl farnesyltransferase inhibitors | ABBOTT LABORATORIES | 2002-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020019527-A1 | Substituted phenyl farnesyltransferase inhibitors | FNTA, FNTB, SLC10A1 | HTR7 4578/4885AR 4525/4885PGR 3080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.